Ascentage Pharma

China - BeijingPharmaceutical1 H-1B visas (FY2023)

Focus: Ascentage Pharma is a China-based oncology-focused pharmaceutical company specializing in small molecule cancer therapeutics. The company operates a diversified portfolio spanning branded oncology assets and generic medications.

Oncology

Profile data last refreshed 10m ago · AI intelligence enriched 2w ago

Open Jobs

About Ascentage Pharma

AI assessmentNot Hiring

No open roles listed right now. Follow Ascentage Pharma to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

3/9 — Basic

Company HealthStrong

Pipeline

Late-stage

4 Phase 3+

LOE Risk

4 in 5yr

MYRBETRIQ

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

MYRBETRIQ

Not specified in labeling data

$2.5B Part D

Peak

Help build intelligence for Ascentage Pharma

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Active oncology pipeline with 25 programs including 7 Phase 3 trials in high-unmet-need cancers (CML, CLL, AML, solid tumors)
Diversified revenue base across branded and generic segments mitigates single-product risk despite MYRBETRIQ concentration
China-headquartered position offers exposure to Asian market expansion and emerging oncology development strategies

Watch Out For

MYRBETRIQ concentration at 90% of revenue with LOE approaching 2030-03-28 creates significant near-term patent cliff exposure ($2.5B at risk)
Zero active job openings reported; opaque hiring activity and limited public pipeline visibility suggest modest organizational scale or low external recruitment

Generated by Claude from Ascentage Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Sole revenue driver (90% of total); beta-3 agonist for overactive bladder faces patent expiration in 2030, creating urgent need for pipeline conversion.

PREDNISOLONE ACETATE

Mild to moderate noninfectious allergic and inflammatory disorders of lid, conjunctiva

$90M Part D

Pre-Launch

Glucocorticoid ophthalmic agent; pre-launch status suggests recent or pending market entry.

PERCOCET

Severe pain requiring opioid analgesic when alternatives are inadequate

$65M Part D

Post-LOE

Post-LOE opioid combination; declining revenue reflects generic competition and restrictive opioid prescribing environment.

SODIUM OXYBATE

Cataplexy and excessive daytime sleepiness in patients age 7+ with narcolepsy

$48M Part D

Post-LOE

CNS depressant for orphan narcolepsy indication; niche market with stable but modest revenue.

KLOR-CON M20

Hypokalemia in patients without metabolic alkalosis, digitalis intoxication

$22M Part D

Post-LOE

Extended-release potassium supplement; mature generic market with commoditized pricing.

KLOR-CON

Hypokalemia in patients without metabolic alkalosis, digitalis intoxication

$11M Part D

Post-LOE

Immediate-release potassium supplement; lower-revenue variant of M20 formulation.

KLOR-CON

Not specified

$11M Part D

LOE Approaching

NDA-form potassium asset nearing LOE; contributes to mature portfolio erosion.

KLOR-CON

Hypokalemia in patients without metabolic alkalosis, digitalis intoxication

$11M Part D

Post-LOE

Duplicate ANDA entry for potassium chloride; reflects fragmented legacy portfolio.

MELOXICAM

Nonsteroidal anti-inflammatory use

$11M Part D

Post-LOE

Generic NSAID; highly competitive commodity market with minimal differentiation.

ESCITALOPRAM OXALATE

Anxiety

$8M Part D

Post-LOE

Generic SSRI; smallest revenue contributor; exemplifies mature portfolio in terminal decline.

Pipeline & Clinical Trials

APG-5918

Advanced Solid Tumors

Phase 1

Clinical Trials (2)

NCT05773586A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of APG-5918.

Phase 1

NCT05415098Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas

Phase 1

[14C ]APG-2575

Pharmacokinetics

Phase 1

Clinical Trials (1)

NCT05517616The Absorption, Metabolism and Excretion of [14C]APG-2575 in Healthy Subjects

Phase 1

APG-2575

Hematologic Malignancies

Phase 1

Clinical Trials (5)

NCT06389292A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia

Phase 3

NCT06641414Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).

Olverembatinib 20mg

Pharmacokinetic

Phase 1

Clinical Trials (1)

NCT07282093Pharmacokinetics of Olverembatinib in Participants With Hepatic Impairment

Phase 1

APG-2575

Chronic Lymphocytic Leukemia

Phase 1

Clinical Trials (1)

NCT03913949A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies

Phase 1

APG2575 400 mg

Waldenstrom Macroglobulinemia

Phase 1

Clinical Trials (1)

NCT04260217APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia

Phase 1

Pelcitoclax

Relapsed/Refractory Acute Myeloid Leukemia

Phase 1

Clinical Trials (2)

NCT07428486A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia

Phase 1

NCT04893759A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors

APG-3288

Relapsed/Refractory Hematological Malignancies

Phase 1

Clinical Trials (1)

NCT07424833A Study of APG-3288 in Relapsed/Refractory Blood Cancers

Phase 1

APG-2449

Advanced Solid Tumors

Phase 1

Clinical Trials (2)

NCT06687070APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST

Phase 1

NCT03917043APG-2449 in Patients With Advanced Solid Tumors

Phase 1

APG-1252

Solid Tumors

Phase 1/2

Clinical Trials (5)

NCT04210037Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer

Phase 1/2

NCT04354727A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy

Phase 1/2

APG-2575

Chronic Lymphocytic Leukemia

Phase 1/2

Clinical Trials (1)

NCT04494503Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL

Phase 1/2

APG-2575+ Pd

Multiple Myeloma

Phase 1/2

Clinical Trials (1)

NCT04942067APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma

Phase 1/2

APG-2575

SLE

Phase 1/2

Clinical Trials (1)

NCT06182969A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.

Phase 1/2

APG-2575

Breast Cancer

Phase 1/2

Clinical Trials (1)

NCT04946864A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer

Phase 1/2

APG-2575

Multiple Myeloma

Phase 1/2

Clinical Trials (1)

NCT04674514APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma

Phase 1/2

APG-115

Advanced Solid Tumors

Phase 1/2

Clinical Trials (5)

NCT04358393A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS

Phase 1/2

NCT03781986APG-115 in Salivary Gland Cancer Trial

Phase 1/2

APG 2575 ramp up arm

AML, Adult

Phase 1/2

Clinical Trials (1)

NCT04964518A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)

Phase 1/2

APG-1387

Advanced Solid Tumors

Phase 1/2

Clinical Trials (5)

NCT04568265A Clinical Study of APG-1387 in Combination With Entecavir in Patients With Chronic Hepatitis B

Phase 2

NCT04643405APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma

Phase 1/2

olverembatinib

Chronic Myeloid Leukemia

Phase 2

Clinical Trials (1)

NCT06817720Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

Phase 2

Blinatumomab

Phase II Clinical Trial

Phase 2

Clinical Trials (1)

NCT04260022Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

Phase 1

APG2575

Chronic Lymphocytic Leukemia

Phase 2

Clinical Trials (2)

NCT06104566Global Trial in APG2575 for Patients With CLL/SLL

Phase 3

NCT05147467Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL

Phase 2

Olverembatinib

Ph+ ALL

Phase 3

Clinical Trials (4)

NCT06423911Study of Olverembatinib (HQP1351) in Patients With CP-CML

Phase 3

NCT06051409A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)

Phase 3

HQP1351

Chronic Myeloid Leukemia

Phase 3

Clinical Trials (5)

NCT04126681A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase

Phase 2

NCT03883087A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Chronic Phase With T315I Mutation

lisaftoclax

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Phase 3

Olverembatinib

GIST

Phase 3

Clinical Trials (1)

NCT06640361A Study of Olverembatinib in SDH-deficient GIST.

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 208 approved products, 57 clinical trials

Top TAs: Oncology, Neurology, Musculoskeletal

H-1B (2023): 1 approval

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Portfolio Health

Pre-Launch17 (8%)

Peak11 (5%)

LOE Approaching13 (6%)

Post-LOE167 (80%)

208 total products

Therapeutic Area Focus

Oncology

4 marketed40 pipeline

32 marketed

18 marketed

17 marketed

13 marketed

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

BEXAROTENE

bexarotene

(RXRα, RXRβ, RXRγ). RXRs can form heterodimers with various receptor partners such as retinoic acid receptors (RARs), vitamin D receptor, thyroid receptor, and peroxisome proliferator activator receptors (PPARs). Once activated, these receptors function as transcription factors that regulate the expression of genes that control cellular differentiation and proliferation. Bexarotene inhibits the growth in vitro of some tumor cell lines of hematopoietic and squamous cell origin. It also induces tumor regression in vivo in some animal models. The exact mechanism of action of bexarotene in the treatment of cutaneous T-cell lymphoma (CTCL) is unknown.

NCT06319456A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.

Phase 3

NCT05186012APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma

Phase 1/2

NCT04785196APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors

Phase 1/2

NCT04284488Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors

Phase 1/2

NCT06401603A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia

Phase 1

NCT03883100A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation

Phase 2

Respiratory

13 marketed

Nephrology

6 marketed

Immunology

4 marketed

Ascentage Pharma

About Ascentage Pharma

Why Work Here

Key Products

Watch Out For

Products & Portfolio (40)

Key Products by Revenue

Other Products (37)

Pipeline & Clinical Trials

Open Jobs (0)

Visa Sponsorship